🇺🇸 FDA
Patent

US 10508106

Bicyclic BET bromodomain inhibitors and uses thereof

granted A61PA61P25/28A61P31/18

Quick answer

US patent 10508106 (Bicyclic BET bromodomain inhibitors and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61P, A61P25/28, A61P31/18, A61P35/00, A61P35/02